Lawsuits filed allege that drug companies ignored significant evidence of these risks and continued to market these drugs as safe weight loss medications
You should contact your GP if body odour changes are accompanied by: Persistent gastrointestinal symptoms such as nausea or vomiting Signs of dehydration including dark urine, dizziness, reduced urination, or extreme thirst Unexplained fever, night sweats, or weight loss exceeding expected rates, which could suggest infection or other medical conditions Skin changes such as rashes, excessive sweating, or fungal infections in body folds Mood changes or anxiety related to body odour concerns affecting your quality of life According to the Wegovy SmPC, you should seek urgent medical attention if you experience severe, persistent abdominal pain (with or without vomiting) which could indicate pancreatitis, or upper right abdominal pain, fever, nausea and yellowing of the skin or eyes which may suggest gallbladder problems
On average, GLP-1 use leads to a modest amount of weight loss, averaging between 5-10% of body weight, while some users may not experience any weight changes
If you are comparing receptor overlap and stacking risk, read our retatrutide and semaglutide together safety guide
GLP-1 drugs are essentially the next generation of that playbook: powerful new drugs that are like supercharged versions of our own hunger-checking hormones, which can help athletes get lean
Tirzepatide brand names you may recognize are Zepbound and Mounjaro
